Celon Pharma (WAR:CLN) Cyclically Adjusted Revenue per Share: zł4.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CLN Celon Pharma SA WAR:CLN
44 GF Score
Price zł21.10
GF Value zł23.82
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Cyclically Adjusted Revenue per Share?

Celon Pharma WAR:CLN +0.48% 44 Cyclically Adjusted Revenue per Share is zł4.16 as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 44/100 and a GF Value™ of zł23.82 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Celon Pharma's adjusted revenue per share for the three months ended in Mar. 2026 was zł1.071. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł4.16 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-20), Celon Pharma's current stock price is zł21.10. Celon Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł4.16. Celon Pharma's Cyclically Adjusted PS Ratio of today is 5.07.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Celon Pharma was 5.59. The lowest was 4.61. And the median was 5.05.


Celon Pharma  (WAR:CLN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Celon Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.10/4.16
=5.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Celon Pharma was 5.59. The lowest was 4.61. And the median was 5.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Celon Pharma Cyclically Adjusted Revenue per Share Related Terms


Celon Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Cyclically Adjusted Revenue per Share Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 4.08 0.00 4.16

WAR:CLN vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Cyclically Adjusted PS Ratio falls into.


WAR:CLN
44GF Score
Celon Pharma SA WAR:CLN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celon Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.071/163.0700*163.0700
=1.071

Current CPI (Mar. 2026) = 163.0700.

Celon Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.668 99.552 1.094
201609 0.498 99.064 0.820
201612 1.056 100.366 1.716
201703 0.631 101.018 1.019
201706 0.636 101.180 1.025
201709 0.538 101.343 0.866
201712 0.576 102.564 0.916
201803 0.626 102.564 0.995
201806 0.672 103.378 1.060
201809 0.704 103.378 1.110
201812 0.781 103.785 1.227
201903 0.602 104.274 0.941
201906 0.529 105.983 0.814
201909 0.563 105.983 0.866
201912 0.600 107.123 0.913
202003 0.679 109.076 1.015
202006 0.904 109.402 1.347
202009 0.670 109.320 0.999
202012 0.881 109.565 1.311
202103 1.014 112.658 1.468
202106 1.092 113.960 1.563
202109 0.820 115.588 1.157
202112 0.860 119.088 1.178
202203 0.657 125.031 0.857
202206 0.898 131.705 1.112
202209 0.769 135.531 0.925
202212 0.889 139.113 1.042
202303 0.782 145.950 0.874
202306 0.831 147.009 0.922
202309 0.811 146.113 0.905
202312 0.775 147.741 0.855
202403 0.688 149.044 0.753
202406 1.049 150.997 1.133
202409 0.941 153.439 1.000
202412 0.721 154.660 0.760
202503 0.919 157.021 0.954
202506 0.961 157.509 0.995
202509 0.988 158.000 1.020
202512 0.000 158.320 0.000
202603 1.071 163.070 1.071

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł4.16 mean?
Celon Pharma (WAR:CLN) has a Cyclically Adjusted Revenue per Share of zł4.16 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Cyclically Adjusted Revenue per Share too high?
Celon Pharma's current Cyclically Adjusted Revenue per Share is zł4.16. Overall, Celon Pharma has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Celon Pharma's Cyclically Adjusted Revenue per Share of zł4.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Celon Pharma and its competitors. Celon Pharma's current Cyclically Adjusted Revenue per Share is zł4.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.82, compared to a current price of zł21.10 — trading 11.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł4.16. Celon Pharma's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Cyclically Adjusted Revenue per Share is zł4.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł21.10 is trading 11.4% below its estimated GF Value™ of zł23.82. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Cyclically Adjusted Revenue per Share: zł4.16
  • GF Value™: zł23.82 vs. price of zł21.10 (11.4% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
44GF Score

Get the complete analysis for WAR:CLN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł21.10
Price
zł23.82
GF Value